• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Exscientia Ltd ADR (NQ: EXAI )

    5.820 +0.270 (+4.86%)
    Streaming Delayed Price Updated: 2:13 PM EDT, Aug 29, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 584,821
    Open 5.490
    Bid (Size) 5.810 (3)
    Ask (Size) 5.830 (2)
    Prev. Close 5.550
    Today's Range 5.430 - 5.904
    52wk Range 3.800 - 7.910
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Exscientia to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
    From Exscientia plc
    Via Business Wire
    Our AI-Focused Drug Discovery Stocks Portfolio Was Up Almost 7% Last Week
    The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030. 
    Via Talk Markets

    Performance

    YTD
    -6.95%
    -6.95%
    1 Month
    +9.81%
    +9.81%
    3 Month
    +24.63%
    +24.63%
    6 Month
    -13.39%
    -13.39%
    1 Year
    -6.28%
    -6.28%

    More News

    Read More
    The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why.
    Via The Motley Fool
    EXAI Stock Earnings: Exscientia Misses EPS, Misses Revenue for Q2 2024
    Via InvestorPlace
    Exscientia Business Update for Second Quarter and First Half 2024
    From Exscientia plc
    Via Business Wire
    AI-Focused Drug Discovery Stocks Portfolio Hit Hard: Down 14% MTD
    Via Talk Markets
    How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates
    Via FinancialNewsMedia
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia?
    Via The Motley Fool
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals
    Via Benzinga
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates
    From FN Media Group LLC
    Via GlobeNewswire
    Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities
    From Recursion Pharmaceuticals, Inc.
    Via GlobeNewswire
    AI-Focused Drug Discovery Stocks Portfolio Up 7% Last Week; Up 19% MTD
    Via Talk Markets
    AI-Powered Drug Discovery Stocks Portfolio Up 14% MTD; Still Down 30% YTD
    Via Talk Markets
    Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout
    From Exscientia plc
    Via Business Wire
    Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
    Via Talk Markets
    Exscientia Launches AWS AI-powered Platform to Advance Drug Discovery
    From Exscientia plc
    Via Business Wire
    3 Small-Cap Stocks With Explosive 2X Growth Potential
    Via InvestorPlace
    Clinical-Stage BioTech Drug Stocks Declined 13% In June
    Via Talk Markets
    EXAI Investors Have Opportunity to Lead Exscientia plc Securities Fraud Lawsuit with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Exscientia p.l.c. (EXAI)
    From The Law Offices of Frank R. Cruz
    Via Business Wire
    EXAI FINAL DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Exscientia p.l.c. Investors to Secure Counsel Before Important June 25 Deadline in Securities Class Action – EXAI
    From The Rosen Law Firm PA
    Via GlobeNewswire
    EXAI Investors Have Opportunity to Lead Exscientia plc Securities Fraud Lawsuit with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    Largest Clinical-Stage BioTech Drug Stocks Declined 6%
    Via Talk Markets
    EXSCIENTIA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Exscientia plc. and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Exscientia
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.